Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Viking Therapeutics (VKTX) over the last 11 years, with Q4 2025 value amounting to $41000.0.

  • Viking Therapeutics' Gains from Investment Securities changed N/A to $41000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $150000.0, marking a year-over-year decrease of 9964.46%. This contributed to the annual value of $5.1 million for FY2025, which is 803.25% up from last year.
  • According to the latest figures from Q4 2025, Viking Therapeutics' Gains from Investment Securities is $41000.0.
  • In the past 5 years, Viking Therapeutics' Gains from Investment Securities ranged from a high of $42.1 million in Q1 2024 and a low of $41000.0 during Q4 2025
  • Moreover, its 5-year median value for Gains from Investment Securities was $4.5 million (2021), whereas its average is $6.1 million.
  • In the last 5 years, Viking Therapeutics' Gains from Investment Securities plummeted by 88.02% in 2024 and then soared by 464525.87% in 2025.
  • Viking Therapeutics' Gains from Investment Securities (Quarter) stood at $3.9 million in 2021, then skyrocketed by 30.03% to $5.1 million in 2022, then rose by 1.04% to $5.2 million in 2023, then crashed by 97.89% to $109000.0 in 2024, then plummeted by 62.39% to $41000.0 in 2025.
  • Its Gains from Investment Securities stands at $41000.0 for Q4 2025, versus $5.2 million for Q3 2025 and $5.2 million for Q2 2025.